House Dust Mite Allergen Reduction in Bedding: Purotex Impregnated Covers of Bekaert Textiles

NCT01997606 | Completed

• 1 other identifier: 2012/398
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Product information: Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. Study design:

• Placebo-controlled: the effect of the Purotex impregnated mattress and pillow covers will be compared to untreated, classical bedding covers (placebo).
• Cross-over design: There will be 2 'treatment' arms. One arm (Arm 1) in which the subjects will first use the Purotex impregnated covers (Set A=Purotex) during 2 months (=period A) and, after a wash out period of 1 month, the untreated covers (set B=placebo) during 2 months (=period B). In the second arm (Arm 2), the subjects will first use the untreated set (set A=placebo) and, after a wash out period the Purotex impregnated covers (set B=Purotex).
• Randomized: The subjects will be randomly assigned to one of the 2 treatment arms.
• Double blind: both the subjects and the investigators will not know to which treatment arm the subjects are assigned. Study hypothesis: We want to investigate:
• if there is a reduced concentration of HDM allergen in Purotex covers compared to untreated covers in real life
• if patients with allergic rhinitis to house dust mite use the Purotex covers, they experience an improvement of their quality of life and sleep, and an improvement of their allergic symptoms and global discomfort

Conditions

Allergic Rhinitis

Outcome Measures

Primary Outcomes (1)

• Change in house dust mite allergen concentration

  Concentration of house dust mite allergen in dust collected from the mattress and pillow covers will be measured by using ELISA During the study, the patients will collect dust every 2 weeks (for each cover their will be 5 time points with an interval of 2 weeks on which dust will be collected)

  every two weeks, starting after randomisation untill completion of the study (5 months after randomisation)

Secondary Outcomes (6)

• Change in quality of life

  every week during the course of the study (from baseline untill 5 months after)

• change in quality of sleep

  every week during the course of the study (from start till 5 months)

• change in control of allergic rhinitis symptoms

  every week during the course of the study (from baseline till month 5)

• change in global discomfort

  every week during the course of the study (from baseline till month 5)

• change in use of rescue medication

  every week during the course of the study (from baseline till month 5)

Study Arms (2)

Purotex

EXPERIMENTAL

use of Purotex treated bedding covers

Other: use of Purotex treated bedding covers

Placebo

PLACEBO COMPARATOR

no use of Purotex treated bedding covers

Other: placebo

Interventions

use of Purotex treated bedding covers OTHER

Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).

Purotex

placebo OTHER

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be willing to give/sign informed consent
• Subjects (male or female) must be at least 18 years old and maximum 65 years old at screening
• Clinical history of allergic rhinitis for at least 1 year
• Positive skin prick test for D. Pteronyssinus ± D. Farinae
• Positive nasal provocation test with the house-dust-mite allergen
• Specific IgE: Unicap positive to D. Pteronyssinus (d1) and D. Farinae (d2) (\> 0.7U/ml)
• VAS score for global discomfort caused by nasal- or other allergic symptoms during the previous 4 weeks ≥ 5.
• The concentration of Der p1 in the dust collected from own bedding (mattress and pillow), measured by ELISA is above the detection limit (≥ 0.488 ng/ml).

You may not qualify if:

• Patients sensitized to animals should not be included if they are symptomatic upon exposure and regularly exposed to animals: positive SPT to pets and pets at home
• Patients with an allergy to tree pollen (symptoms during the season + positive skin prick test) should not be included
• Subject pregnant or lactating
• Completed allergen specific immunotherapy (SCIT or SLIT) with HDM within the last 5 years
• SCIT or SLIT during the study period
• Regular use of oral corticosteroids for exacerbations of asthma
• Daily use of oral corticosteroids
• Daily use of cyclosporine or other immunosuppressant drugs
• Regular use of antibiotics
• History of anaphylactic reaction to an allergen
• Severe general diseases (especially cardiopulmonary disease with reduced lung capacity)

Sponsors & Collaborators

• University Hospital, Ghent: lead
• Bekaert textiles NV Waregem: collaborator

Study Sites (1)

Ghent University Hospital

Ghent, 9000, Belgium

Location

MeSH Terms

Conditions

Rhinitis, Allergic

Condition Hierarchy (Ancestors)

Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 22, 2013
• First Posted: November 28, 2013
• Study Start: November 1, 2013
• Primary Completion: September 1, 2016
• Study Completion: September 1, 2016
• Last Updated: September 26, 2016

Record last verified: 2016-09

Locations

BE (1)